HealthDay News - Greater willingness to undergo pharmacodynamic, pharmacokinetic tests found with fewer tests
HealthDay News - Patients with advanced malignancies appear to be quite willing to undergo pharmacodynamic (PD) and pharmacokinetic (PK) tests in order to be enrolled in clinical trials, according to research published online Jan. 18 in Cancer.
Raoul Tibes, MD, PhD, of the Mayo Clinic in Scottsdale, Ariz., and colleagues prospectively measured the willingness of 61 patients with advanced malignancies to undergo various procedures and imaging tests, and how many tests patients would tolerate.
The researchers found that, overall, patients' willingness to undergo study-required tests was quite high, more so for blood and urine tests, ultrasounds, X-rays, echocardiograms, and computed tomography than for tumor and skin biopsies and magnetic resonance imaging. There was an inverse relationship between willingness to undergo tests and the frequency of the tests. Willingness was modestly influenced by inconvenience and prior bad experiences with invasive testing, and positively correlated with college education, insurance coverage, and requirement of the tests for enrollment.
"The current findings provide the first prospectively collected data on patients' willingness to undergo PK/PD tests and imaging studies associated with early stage oncology drug trials and can serve as basis for further exploration toward the design of patient-friendly, biomarker-driven clinical studies in oncology," the authors write.
AbstractFull Text (subscription or payment may be required)
Copyright © 2011 HealthDay. All rights reserved.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.